Literature DB >> 22318612

Prostate cancer pain management: EAU guidelines on pain management.

Pia Bader1, Dieter Echtle, Valerie Fonteyne, Kostas Livadas, Gert De Meerleer, Alvaro Paez Borda, Eleni G Papaioannou, Jan H Vranken.   

Abstract

CONTEXT: The first publication of the European Association of Urology (EAU) guidelines on Pain Management in Urology dates back to 2003. Since then, these guidelines have been revised several times with the most recent update achieved in 2010.
OBJECTIVE: Given the scope of the full text guidelines, condensing the entire document was no option in this context. This paper presents a summary of the section of pain management in prostate cancer, a topic considered of direct relevance for the practicing urologist. EVIDENCE ACQUISITION: A multidisciplinary expert panel (urologists, anaesthesiologists, radio-oncologists) compiled this document based on a comprehensive consultation of the literature. Data were identified through a structured search, covering the time frame 2000 through 2010, using Medline and Embase as well as the Cochrane Library of systematic reviews. The scientific papers were weighed by the expert panel and a level of evidence (LE) assigned. Recommendations have been graded as a means to provide transparency between the underlying evidence and the guidance provided. Pain can occur in each stage of prostate cancer. It could be caused by the cancer itself (77%), be related to the cancer treatment (19%) or be unrelated to either (3%). The incidence of pain rises to 90% as patients enter the terminal phase of their illness. The physician's task is to discover and treat the cause of pain and the pain itself, to determine whether or not the underlying cause is treatable, to provide pain relief and palliative care. These tasks more often than not require a multidisciplinary team. Pain management involves mainly pharmacotherapy, including direct anticancer therapy such as androgen deprivation and chemotherapy, as well as analgetics, for instance non-steroidal anti-inflammatory drugs (NSAIDs) or opioids. In case of local impairment due to the cancer or its metastases, primary treatments like surgery, radiotherapy or radionuclides can provide adequate pain relief. In addition, in palliative care, functional, psychosocial and spiritual support are essential components. The EAU guidelines on Pain Management in Urology are available in a number of different formats through the EAU Central Office and the EAU website ( http://www.uroweb.org/guidelines/online-guidelines/ ).
CONCLUSION: The mainstay of pain management in prostate cancer is involvement of and collaboration between experts from a number of disciplines to be able to achieve a complete pain evaluation and to offer the full range of treatment options. Prostate cancer-related pain can, in most cases, be managed effectively, but it requires careful monitoring where a balance should be found between pain relief and potential side effects of treatment and quality of life (QoL).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22318612     DOI: 10.1007/s00345-012-0825-1

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  54 in total

Review 1.  Cancer pain relief and palliative care. Report of a WHO Expert Committee.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1990

Review 2.  The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel.

Authors:  Fred Saad; Celestia S Higano; Oliver Sartor; Marc Colombel; Robin Murray; Malcolm D Mason; Andrea Tubaro; Claude Schulman
Journal:  Clin Genitourin Cancer       Date:  2006-03       Impact factor: 2.872

3.  Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life.

Authors:  S Grond; D Zech; S A Schug; J Lynch; K A Lehmann
Journal:  J Pain Symptom Manage       Date:  1991-10       Impact factor: 3.612

4.  The role of percutaneous nephrostomy in malignant ureteric obstruction.

Authors:  J R Wilson; G H Urwin; M J Stower
Journal:  Ann R Coll Surg Engl       Date:  2005-01       Impact factor: 1.891

5.  Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).

Authors:  P H Coluzzi; L Schwartzberg; J D Conroy; S Charapata; M Gay; M A Busch; J Chavez; J Ashley; D Lebo; M McCracken; R K Portenoy
Journal:  Pain       Date:  2001-03       Impact factor: 6.961

6.  Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group.

Authors:  S Ahmedzai; D Brooks
Journal:  J Pain Symptom Manage       Date:  1997-05       Impact factor: 3.612

Review 7.  Medical and surgical palliative care of patients with urological malignancies.

Authors:  Joon-Ha Ok; Frederick J Meyers; Christopher P Evans
Journal:  J Urol       Date:  2005-10       Impact factor: 7.450

Review 8.  Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain.

Authors:  Fabio M Paes; Aldo N Serafini
Journal:  Semin Nucl Med       Date:  2010-03       Impact factor: 4.446

9.  A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.

Authors:  I Resche; J F Chatal; A Pecking; P Ell; G Duchesne; R Rubens; I Fogelman; S Houston; A Fauser; M Fischer; D Wilkins
Journal:  Eur J Cancer       Date:  1997-09       Impact factor: 9.162

10.  Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.

Authors:  A J Clark; S H Ahmedzai; L G Allan; F Camacho; G L A Horbay; U Richarz; K Simpson
Journal:  Curr Med Res Opin       Date:  2004-09       Impact factor: 2.580

View more
  6 in total

1.  Auditing Analgesic Use in Post-operative Setting in a Teaching Hospital.

Authors:  Sumana Sen; Prapthi Bathini
Journal:  J Clin Diagn Res       Date:  2015-04-01

2.  Spine Pain and Metastatic Prostate Cancer: Defining the Contribution of Nonmalignant Etiologies.

Authors:  Lisa Marie Ruppert; Erica Dayan Cohn; Niamh M Keegan; Abigail Bacharach; Sungmin Woo; Theresa Gillis; Howard I Scher
Journal:  JCO Oncol Pract       Date:  2022-02-17

3.  Pain questionnaire performance in advanced prostate cancer: comparative results from two international clinical trials.

Authors:  Donald W Robinson; Ning Zhao; Fitzroy Dawkins; Ming Qi; Dennis Revicki
Journal:  Qual Life Res       Date:  2013-04-16       Impact factor: 4.147

Review 4.  Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise.

Authors:  Semini Sumanasuriya; Johann De Bono
Journal:  Cold Spring Harb Perspect Med       Date:  2018-06-01       Impact factor: 6.915

5.  Use of a specific questionnaire and perineal electromyography to assess neuropathic pain after radical retropubic prostatectomy.

Authors:  Nicolas Turmel; Samer Sheikh Ismael; Camille Chesnel; Audrey Charlanes; Claire Hentzen; Frédérique Le Breton; Gérard Amarenco
Journal:  Asian J Urol       Date:  2018-06-21

Review 6.  Incorporating palliative care principles to improve patient care and quality of life in urologic oncology.

Authors:  Lee A Hugar; Elizabeth M Wulff-Burchfield; Gary S Winzelberg; Bruce L Jacobs; Benjamin J Davies
Journal:  Nat Rev Urol       Date:  2021-07-26       Impact factor: 14.432

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.